SCHEMBL9983804

SCHEMBL9983804

CC(C)(C)OC(=O)NC1CCN(c2ccc(Nc3nc(Cl)ccc3[N+](=O)[O-])cc2F)CC1

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SYK P43405 3/20 0.41
AAK1 Q2M2I8 1/20 0.41
CKS1B P61024 1/20 0.40
SKP1 P63208 1/20 0.40
SKP2 Q13309 1/20 0.40
DRD2 P14416 3/20 0.39
DRD3 P35462 1/20 0.38
SUV39H2 Q9H5I1 2/20 0.38
RET P07949 1/20 0.38
ROS1 P08922 1/20 0.38
FLT3 P36888 1/20 0.38
EML4 Q9HC35 1/20 0.38
ALK Q9UM73 1/20 0.38
F10 P00742 1/20 0.38
MAPT P10636 2/20 0.38
MAPK1 P28482 1/20 0.38
EGFR P00533 1/20 0.37
FGFR4 P22455 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9985257 0.84 MAPT (0.48) RETROS1FLT3EML4ALK
SCHEMBL9987980 0.84 TDP1 (0.49) MAPTL3MBTL1
SCHEMBL9985521 0.83 MAPT (0.57) SYKRETROS1FLT3EML4
SCHEMBL27227414 0.82 SIGMAR1 (0.44) AAK1DRD2DRD3MAPTL3MBTL1
SCHEMBL9984259 0.80 ALDH1A1 (0.50) MAPTMAPK1FGFR4L3MBTL1
SCHEMBL9984378 0.80 SYK (0.37) SYKRETROS1FLT3EML4
SCHEMBL9984369 0.79 FGFR4 (0.35) SYKMAPTMAPK1FGFR4L3MBTL1
SCHEMBL21643974 0.79 MAPT (0.47) SYKMAPTMAPK1FGFR4
SCHEMBL9985022 0.79 FGFR4 (0.42) MAPTMAPK1FGFR4L3MBTL1
SCHEMBL4439214 0.78 DRD2 (0.47) CKS1BSKP1SKP2DRD2DRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110306606-A1 NOVEL 2,6-SUBSTITUTED-3-NITROPYRIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME DONG WHA PHARM. CO., LTD. (KR) 2011-12-15 US disclosed
EP-2394993-A2 NOVEL 2,6-SUBSTITUTED-3-NITROPYRIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME Dong Wha Pharm. Co., Ltd. (KR) 2011-12-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110306606-A1 NOVEL 2,6-SUBSTITUTED-3-NITROPYRIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME NOS3, PTMS, NOS2 SYK 1244/4885AAK1 2481/4885CKS1B 1709/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.